Cellectar Biosciences, Inc. announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers. Under the terms of the agreement, Cellectar has an exclusive license to develop and commercialize iopofosine in various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | -0.90% | +7.49% | +19.13% |
05-14 | Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.13% | 118M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation